Pasithea Therapeutics Corp.Pasithea Therapeutics Corp.Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪6.10 M‬USD
−14.30USD
‪−15.96 M‬USD
‪740.22 K‬
Beta (1Y)
1.06

About Pasithea Therapeutics Corp.

CEO
Tiago Reis Marques
Headquarters
Miami Beach
Employees (FY)
8
Founded
2020
FIGI
BBG01018ZGY8
Pasithea Therapeutics Corp. is a biotechnology company focuses on the research and discovery of new and treatments for psychiatric and neurological disorders. The company was founded by Yassine Bendiabdallah and Steinman Lawrence J in May, 2020 and is headquartered in Miami Beach, FL.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of KTTA is 5.80 USD — it has decreased by 0.85% in the past 24 hours. Watch Pasithea Therapeutics Corp. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Pasithea Therapeutics Corp. stocks are traded under the ticker KTTA.
KTTA stock has risen by 4.38% compared to the previous week, the month change is a 18.85% rise, over the last year Pasithea Therapeutics Corp. has showed a 50.68% decrease.
KTTA reached its all-time high on Nov 23, 2021 with the price of 170.00 USD, and its all-time low was 4.74 USD and was reached on Jun 21, 2024. View more price dynamics on KTTA chart.
See other stocks reaching their highest and lowest prices.
KTTA stock is 10.18% volatile and has beta coefficient of 1.06. Track Pasithea Therapeutics Corp. stock price on the chart and check out the list of the most volatile stocks — is Pasithea Therapeutics Corp. there?
Today Pasithea Therapeutics Corp. has the market capitalization of ‪6.10 M‬, it has increased by 2.86% over the last week.
Yes, you can track Pasithea Therapeutics Corp. financials in yearly and quarterly reports right on TradingView.
Pasithea Therapeutics Corp. is going to release the next earnings report on Aug 28, 2024. Keep track of upcoming events with our Earnings Calendar.
KTTA net income for the last quarter is ‪−3.86 M‬ USD, while the quarter before that showed ‪−5.05 M‬ USD of net income which accounts for 23.52% change. Track more Pasithea Therapeutics Corp. financial stats to get the full picture.
No, KTTA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jul 22, 2024, the company has 8.00 employees. See our rating of the largest employees — is Pasithea Therapeutics Corp. on this list?
Like other stocks, KTTA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Pasithea Therapeutics Corp. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Pasithea Therapeutics Corp. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Pasithea Therapeutics Corp. stock shows the sell signal. See more of Pasithea Therapeutics Corp. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.